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Zanamivir is a highly selective neuraminidase (NA) inhibitor with demonstrated clinical efficacy against
influenza A and B virus infections. In phase II clinical efficacy trials (NAIB2005 and NAIB2008), virological
substudies showed mean reductions in virus shedding after 24 h of treatment of 1.5 to 2.0 log10 50% tissue
culture infective doses compared to a placebo, with no reemergence of virus after the completion of therapy.
Paired isolates (n 5 41) obtained before and during therapy with zanamivir demonstrated no shifts in
susceptibility to zanamivir when measured by NA assays, although for a few isolates NA activity was too low
to evaluate. In plaque reduction assays in MDCK cells, the susceptibility of isolates to zanamivir was extremely
variable even at baseline and did not correlate with the speed of resolution of virus shedding. Isolates with
apparent limited susceptibility to zanamivir by plaque reduction proved highly susceptible in vivo in the ferret
model. Further sequence analysis of paired isolates revealed no changes in the hemagglutinin and NA genes
in the majority of isolates. The few changes observed were all natural variants. No amino acid changes that had
previously been identified in vitro as being involved with reduced susceptibility to zanamivir were observed.
These studies highlighted problems associated with monitoring susceptibility to NA inhibitors in the clinic, in
that no reliable cell-based assay is available. At present the NA assay is the best available predictor of
susceptibility to NA inhibitors in vivo, as measured in the validated ferret model of infection.
Influenza is a respiratory infection that produces significant
seasonal morbidity in the general population and excess mor-
tality particularly in high-risk groups, including the elderly and
those with underlying chronic disease. Both influenza A and
influenza B viruses are responsible for human disease. Anti-
genic drift in these viruses results from mutations within the
genes encoding the two surface glycoproteins, the hemagglu-
tinin (HA) and the neuraminidase (NA) proteins. Control by
vaccination requires the yearly prediction of circulating influ-
enza A and B strains and annual vaccination, incorporating
current A and B strains. Of the 15 HA and 9 NA subtypes of
influenza A, relatively few have produced pandemics in man.
However, the potential exists for interspecies transmission and
the emergence of further pandemics (30). Additional control
measures, including the use of antiviral agents, are therefore
important.
Zanamivir (5-acetylamino-2, 6-anhydro-4-guanidino-3, 4,
5-trideoxy-D-glycerol-D-galacto-non-2-enoic acid, also known
as GG167) is a potent and selective NA inhibitor that interacts
with conserved residues in the active site of the NA enzyme
and is effective against all nine NA subtypes of influenza A and
B virus NA (10, 28). Zanamivir inhibits a wide range of labo-
ratory and clinical isolates of influenza A and B viruses in vitro
and in vivo (24, 25, 31) and has been shown to be effective in
human experimental influenza challenge and field studies (11,
13, 19).
Amantadine and rimantadine, the first specific anti-influ-
enza agents, described over 30 years ago, have limited clinical
value because they are effective only against influenza A virus
and can both cause side effects. Furthermore, drug-resistant
viruses readily emerge during therapy with amantadine or
rimantadine in up to 30% of subjects with acute influenza
infections (20). These resistant strains appear to be fully patho-
genic and are transmissible to close contacts (12, 14, 15).
Based on knowledge of the X-ray crystal structure of influ-
enza virus NA, zanamivir was designed to bind only to highly
conserved residues within the active site of influenza A and B
virus NA (29); as a result, there should be constraints on the
development of resistance and the maintenance of NA enzyme
function. However, it is important to determine the potential
for the development of variants with reduced susceptibility to
zanamivir during therapy. From in vitro studies with zanamivir,
resistant variants have been isolated in passage experiments
after prolonged exposure to the compound, with changes in
either the HA or NA gene or both (1, 2, 8, 9, 17, 21, 27). These
in vitro studies demonstrated the potential for resistance de-
velopment and confirmed that neuraminidase variants had re-
duced stability or enzyme function. The relevance of the in
vitro observations to clinical settings is not known. Phase I
influenza challenge studies have been reported where influ-
enza virus clinical isolates obtained before and during treat-
ment of experimental influenza virus infection have been eval-
uated for their susceptibility to zanamivir (13). During 5 days
of treatment of acute influenza infection with zanamivir, no
influenza virus isolates with reduced susceptibility were re-
ported. However, there has been one report of mutations oc-
curring within the HA and NA genes in a single clinical isolate
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following delayed and prolonged treatment of influenza B in-
fection in an immunocompromised patient (7). The clinical
significance of these mutations has not yet been elucidated, but
the virus has significantly reduced infectivity in the ferret
model.
As part of the clinical evaluation of zanamivir in acute in-
fluenza infection in adults, virological substudies described in
this study were undertaken in the phase II clinical trials
NAIB2005 and NAIB2008. The clinical details of these two
studies have been reported previously (11, 19). Briefly, in
NAIB2005, adults with an influenza-like illness of ,48-h du-
ration were treated twice daily (BID) for 5 days with zanamivir
or a placebo administered by oral inhalation (IH) (10 mg/dose)
or by a combination of IH and intranasal (IN) spray (6.4
mg/dose). Hayden et al. (11) reported that with zanamivir
treatment (in study NAIAB2005), clinical recovery time was
reduced by up to 3 days in those with febrile illness when
treatment was initiated early. In study NAIAB2008, adults with
influenza-like illness of ,48-h duration were treated BID or
four times daily (QID) for 5 days with zanamivir or a placebo
administered by both the IH and IN routes (19). Similar clin-
ical efficacy in the overall population was observed with either
the BID or the QID regimen, with a median reduction in the
duration of major symptoms of 1 day in the treated group.
The aim of these virological substudies from the two phase
II clinical trials was to evaluate the effects of zanamivir on virus
shedding and to monitor the zanamivir susceptibility of influ-
enza clinical isolates obtained before and during therapy.
Some isolates were also evaluated in the in vivo ferret model to
elucidate the significance of the variability observed in the in
vitro assays. Further evaluation of the influenza virus clinical
isolates obtained included a comprehensive sequence analysis
of both the HA and NA genes. The findings from this detailed
analysis of influenza clinical isolates obtained during zanamivir
treatment are described below together with recommendations
for the most suitable methodology for monitoring the suscep-
tibility of influenza isolates to NA inhibitors.
MATERIALS AND METHODS
Virus. Influenza virus clinical isolates were obtained from nasal washings taken
before, during, and after treatment with either zanamivir or a placebo. All
subjects recruited into protocols NAIB2005 and NAIB2008 at the Erasmus
University Hospital, Rotterdam, The Netherlands, were evaluated in this viro-
logical substudy. The wild-type B/Beijing/1/87 isolate was kindly supplied by M.
Zambon (PHLS, Colindale, United Kingdom). The influenza B zanamivir-resis-
tant variant B/Beijing/1/87 isolate P3-12 (containing HA mutations Val105Ala
and Leu255Gln and NA mutation Glu116Gly) was isolated by in vitro passage at
Glaxo Wellcome Medicines Research Centre, Stevenage, United Kingdom (Bar-
nett et al., submitted for publication).
Cell culture. Madin-Darby canine kidney (MDCK) cells were purchased from
ICN Pharmaceuticals, Ltd., Thame, United Kingdom, and were routinely pas-
saged in Eagle’s modified minimal essential medium (MEM) supplemented with
10% fetal calf serum and 1% nonessential amino acids. Tertiary monkey kidney
(tMK) cells were obtained from cynomolgus macaques and grown in Earle’s
minimal essential medium supplemented with 10% fetal bovine serum.
Reagents and compounds. Indubiose A37 agarose was purchased from IBF
Biotechnics, Villeneuve La Garenne, France. Gluteraldehyde and carbol fuchsin
(Ziehl-Neelsen strong formulation) were purchased from BDH Laboratory Sup-
plies, Poole, United Kingdom. Tolylsulfonyl phenylalanyl chloromethyl ketone
(TPCK)-treated trypsin was purchased from Worthington Biochemical Corpo-
ration, Freehold, N.J. All cell culture media were purchased from the Sigma
Chemical Company, Poole, United Kingdom, except for DCCM-1 (defined cell
culture medium), which was purchased from Biological Industries, Kibbutz Beth
Haemak, Israel. Monoclonal antibodies to influenza A and B virus nucleoprotein
antigens were purchased from TCS Biologicals, Ltd., Botolph, Claydon, Buck-
ingham, United Kingdom. Tissue culture plasticware was purchased from
GIBCO BRL, Paisley, United Kingdom, and Costar Corporation, Cambridge,
Mass. 2-(N-Morpholino)ethanesulphonic acid (MES) and 29-(4-methylumbel-
liferyl)-a-D-N-acetylneuraminic acid (MUN) were purchased from the Sigma
Chemical Company. Black MicroFLUOR 96-well plates were purchased from
Dynatech Laboratories, Inc., Chantilly, Va. Zanamivir was synthesized at Glaxo
Wellcome Medicines Research Centre.
Virus quantitation. Virus titers were determined for the NAIB2005 samples
with both tMK and MDCK cells and for NAIB2008 samples with MDCK cells
only. Briefly, confluent MDCK or tMK cells were infected in quadruplicate with
100 ml of a 10-fold dilution series of the nasal washes (ranging from undiluted to
1025) in serum-free medium containing 1 to 2 mg of trypsin per ml. Virus was
adsorbed for 1 h and then the cells were washed four times to remove unad-
sorbed virus and residual zanamivir. For MDCK cells, cultures were then incu-
bated at 37°C in 5% CO2 for 3 days, and the amount of influenza virus present
was then quantified by enzyme-linked immunosorbent assay (ELISA) with
mouse monoclonal antibodies to influenza A and B virus nucleoproteins. For
tMK cells, cultures were incubated for 6 days and virus was detected by hemag-
glutination with turkey erythrocytes.
Virus isolation. Virus stocks of clinical isolates and mutant influenza A virus
isolates were prepared by inoculating confluent MDCK cells with virus diluted in
serum-free MEM (containing 2 mg of TPCK-treated trypsin per ml). The virus
was allowed to adsorb for 1 h at 37°C and then the volume of medium was
increased to 5 ml before further incubation at 37°C. Virus stocks were harvested
by collecting the supernatant when the cytopathic effect was extensive or after 5
days of incubation. Virus titers were determined by plaque assays, as described
below.
Virus plaque assays. Plaque assays were performed as described previously
(31). Confluent monolayers of MDCK cells in six-well tissue culture plates were
inoculated with 300 ml of influenza virus diluted in serum-free MEM containing
2 mg of TPCK-treated trypsin per ml. Prior to inoculation, the spent medium was
decanted and the cells were washed twice with prewarmed phosphate-buffered
saline. After adsorption at room temperature for 1 h, the cell monolayers were
overlaid with DCCM-1 containing 0.5% agarose and zanamivir at concentrations
ranging from 0.0001 to 100 mg/ml. Two wells of each plate were overlaid with
medium alone so that the number of plaques formed in the absence of zanamivir
could be determined. Once overlaid, the plates were incubated at 37°C in 5%
CO2 for 3 days. After 3 days, the plates were fixed with 5% gluteraldehyde and
stained with carbol fuchsin. The plaques were counted and the percentage of
plaque reduction for each dilution of zanamivir was determined. The concen-
tration of zanamivir required to reduce plaque numbers by 50% (IC50) was then
calculated for each isolate. At least two or three IC50s were determined for each
isolate.
NA enzyme inhibition assay. NA assays (31) use the substrate MUN and are
based on the method of Potier et al. (22). Influenza virus NA activity for each
virus isolate was first titrated by serial twofold dilutions. The concentration of
virus versus NA activity was plotted graphically to determine the virus/enzyme
concentration to be used in subsequent inhibition assays. For zanamivir inhibi-
tion assays, equal volumes of zanamivir and virus were mixed and preincubated
at room temperature for 30 min in Dynatech MicroFLUOR plates. The reaction
was initiated by the addition of buffer (32.5 mM MES [pH 6.5], 4 mM CaCl2),
containing 100 mM MUN substrate. The reaction mixture was incubated at 37°C
for 15 min with shaking, and the reaction was terminated by the addition of 150
ml of 0.014 M NaOH in 83% ethanol. 4-methylumbelliferone was immediately
quantified by fluorometric determination with an LS-50B luminescence spec-
trometer (Perkin-Elmer, Ltd., Beaconsfield, Buckinghamshire, United King-
dom). The excitation wavelength was 365 nm and the emission wavelength was
450 nm. The data were plotted as log zanamivir concentration against fluores-
cence inhibition, and the IC50s were read from the graph. At least two or three
IC50s were determined for each isolate.
Influenza virus infection in ferrets. Groups of three or four female ferrets (750
to 1,050 g) were infected by IN instillation of 250 ml of a single influenza virus
isolate containing either 103.0 PFU/ml (isolate 7249 D1) or 104.0 PFU/ml (isolate
2871 D2 or 7241 D1) while under light anesthesia (isoflurane), as described
previously (24). These challenges had been previously determined as the lowest
input of virus that would consistently result in infection. Ferrets received two
prophylactic doses of zanamivir, at 26 and 2 h prior to infection, and were treated
at 5 h after infection and then twice daily for 5 days. Animals were weighed daily
for 9 days and IN doses of zanamivir of 1, 0.1, or 0.01 mg/kg of body weight/dose,
calculated daily according to animal weight in a volume of 0.25 ml/kg. Virus-
infected control animals were sham dosed with pyrogen-free MilliQ phosphate-
buffered saline only. Nasal washings were taken on days 1 to 9 following chal-
lenge, as described previously (24), and the washings were used in triplicate for
the estimation of virus titer by ELISA. The mean nasal-wash virus titer area
under the curve (AUC) value for each individual ferret was calculated as the
log10 geometric mean of all the ELISA titers determined on days 1 to 9. For each
group of ferrets, the log10 geometric mean AUC was also calculated. Statistical
analysis was undertaken with a Dunnett’s test to evaluate the differences between
controls and treated ferret groups. The concentration of zanamivir that inhibits
nasal virus titers by 90% (the calculated AUC10) was determined as a measure
of susceptibility to zanamivir. Temperature profiles of ferrets were recorded
every 10 min with implanted telemetric transmitters (Dataquest; Data Sciences,
St. Paul, Minn.), prior to and up to 9 days following infection. Body temperature
AUCs were calculated for the period of pyrexic response (0 to 96 h postinfec-
tion); AUCs were computed as the area above and below the preinfection mean.
Pyrexia was defined as the elevation of core body temperature greater than 2
standard deviations (or more) above the preinfection mean temperature for a
period of at least 12 h during the postinfection period. The Duncan’s multiple
range test was used to analyze temperature values between control and treatment
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groups. Data were ranked and tested for homogeneity of variance (Levene’s test)
and normality of distribution (Shapiro-Wilks test).
Sequencing of the HA and NA genes. Clinical isolates were cultured in MDCK
cells and cell supernatant was used to extract viral RNA (vRNA) with the
QiaAmp viral RNA extraction kit (Qiagen; Hilden, Germany). The forward
primer, p7 (59-ACTATCATTGCTTTGAGC-39), was used to prepare cDNA for
the HA genes (23) and the primer N2a (59-GTGAAGATGAATCCAAATCA
A-39) was used for the NA gene of the H3N2 viruses with SuperScript II. Briefly,
1 mg of each forward primer was incubated at 60°C for 10 min with 24 ml of the
viral RNA extract. A reaction mixture containing 100 mM deoxynucleoside
triphosphate mixture (25 mM [each] dATP, TTP, dCTP, and dGTP), 5 ml of 5
mM dithiothreitol, 53 First Strand buffer (Gibco BRL), and 1 ml SuperScript II
reverse transcriptase enzyme (Gibco BRL) was added to each tube and the
reactions were incubated at 42°C for 50 min before the reverse transcriptase
enzyme was inactivated by incubation at 99°C for 1 min. The forward primer p7
and the reverse primer p1184 (59-ATGGCTGCTTGAGTGCTT-39), a vRNA
sense primer, were then used to amplify the cDNA obtained. The PCR mixture
consisted of 1 ml of 103 PCR buffer, 2.5 mM MgCl2, 0.5 U of Taq polymerase
enzyme, 100 mM deoxynucleoside triphosphate mixture (all from Perkin-Elmer
Applied Biosystems) and 300 ng (each) of primers p7 and p1184 as described
above. Cycling conditions for a single round of PCR with the Perkin-Elmer 9600
thermal cycler were as follows: 94°C for 4 min, 1 cycle; then 94°C for 1 min, 50°C
for 1.5 min, and 72°C for 2 min for 35 cycles. Amplicons were visualized by
agarose gel electrophoresis and purified with the Bio101 GeneClean II DNA
purification kit (Anachem, Luton, United Kingdom). The purified DNA was
cycle sequenced with the ABI Terminator BIGDYE cycle sequencing kit and run
on an ABI Prism 377 DNA sequencer (Perkin-Elmer, Foster City, Calif.) ac-
cording to the manufacturer’s instructions. The sequence data was analyzed with
Lasergene software (DNASTAR, Inc.). For sequencing, three additional internal
primers were also used: R792 (59-CAGTATGTCTCCCGGTTT-39), R570 (59-T
GGCATAGTCACGTTCAG-39), and R362 (59-TAAGGGTAACAGTTGCTG-
39) (23). PCR primers p7 and p1184 were also used for sequencing.
The NA gene of the H3N2 virus was amplified and sequenced with the same
conditions except for the primer sets (N2a, 59-GTGAAGATGAATCCAAATC
AA-39 [forward], and N2b, 59-GCGAAAGCTTATATAGGC-39 [reverse]). In-
ternal sequencing primers for the NA gene were as follows: N2c (59-GGTAAC
TACTGTAACATTGCA-39), N2d (59-GAGAACCTTATGTGTCATGCG-39),
N2e (59-CAGGAGTCGGAATCGGTTTGT-39), N2f (59-GTCAGGAAGTGC
TCAGCA-39), and N2g (59-AGTGAAAGGCTGGGCCTT-39). All primers
were synthesized by PE Applied Biosystems and purified by high-performance
liquid chromatography. As for the HA sequence, the PCR primers were also
used for the sequencing reactions. Primer sets for the H1N1 viruses and the
influenza B viruses were recommended by Alan Hay (NIMR, London, United
Kingdom). Primers underlined indicate those used for the PCR; these primers
were also used for sequencing. For the influenza A (H1N1) NA gene, the primers
were as follows: H1N1F1 (59-AGCAAAAGCAGGAGTTTAAAATGA-39),
H1N1F2 (59-TTCTCACTTGGAATGCAGAACCTT-39), H1N1F3 (59-ATAAT
GACCGATGGCCCGAGTAAT-39), H1N1F4 (59-AGGACTAAAAGTAACA
GACTCAGA-39), H1N1R1 (39-CAACTTTTTTGAGGAACAAAGAT-59), H1
N1R2 (39-TCCTGATTTTCATTGTCTGGAGTCT-59), H1N1R3 (39-TATTAC
TGGCTACCGGGCTAATTA-59), and H1N1R4 (39-AAGAGTGAACCTTAC
GTCTTGGAA-59). For the influenza A (H1N1) HA gene, the primers were as
follows: H1A1F1 (59-CAACCAAATGAAAGCAAAACTAC-39), H1A1F2 (59-
CCCTGAGAATGGAACATGTTACCC-39), H1A1F3 (59-GGTATGCTTTCG
CACTGAGTAGAG-39), H1A2F4 (59-ACATTCCATCCATTCAATCCAGAG-
39), H1A2R1 (39-CCCAGAAACGTCACGTCTTATACG-59), H1A1R1 (39-AA
CCTCGGTAACGGCCAAAGTAAC-59), H1A1R2 (39-CCATACGAAAGCG
TGACTCATCTC-59), H1A1R3 (39-TCTTTAAACGATACCGACTGCCTC-5),
and H1A1R4 (39-GGGACTCTTACCTTGTACAATGGG-59). For the influenza
B virus NA gene, the primers were as follows: BNAF1 (59-AGGCCAAAAAT
GAACAATGCTAC-39), BNAF2 (59-GCACTCCTAATTAGCCCTCATAGA-
39), BNAF3 (59-ACAAGAAAGTGCCTGCAATTGCAT-39), BNAF4 (59-GCA
TCAAGGGAGGATTTGTTCATC-39), BNAR1 (39-GGAATGACCTGAATT
AACAAAGAC-59), BNAR2 (39-CGTAGTTCCCTCCTAAACAAGTAG-59),
BNAR3 (39-TGTTCTTTCACGGACGTTAACGTA-59), and BNAR4 (39-CGT
GAGGATTAATCGGGAGTATCT-59). For the influenza B virus HA gene, the
primers were as follows: BHA1F1 (59-ATTGTACTACTCATGGTAGTAACA-
39), BHA1F2 (59-ATGCTTTCCTATAATGCACGACAG-39), BHA1F3 (59-TG
CGCGAGTGGCAGGAGCAAAGTA-39), BHA2F1, (59-ATGGAACCAAAT
ATAGACCTCCTG-39), BHA2R1 (39-ACGAACAAACGAACAATGGTAAT
G-59), BHA1R1 (39-TCTTCCTCCTACCCTTCCTTACTA-59), BHA1R2 (39-A
CGCGCTCACCGTCCTCGTTTCAT-59), and BHA1R4 (39-TACGAAAGGA
TATTACGTGCTGTC-59).
RESULTS
Quantitation of virus shedding. In NAIB2005, a total of 51
subjects were included in the virological subset from which
60% of viruses were typed as influenza B by hemagglutination
inhibition or by sequencing, and the remainder were typed as
influenza A (H3N2). For NAIB2008, 41 subjects were included
in the subset, of which 73% of viruses were typed as influenza
A (H3N2) virus and the remainder were typed as influenza A
(H1N1). Virus titrations were determined for the NAIB2005
samples with both tMK cells and MDCK cells. Both cell lines
gave statistically comparable results. In NAIB2008, virus titra-
tions were undertaken in MDCK cells. All virus titrations were
performed blinded and titers were calculated with the Spear-
man-Karber equation (5). For comparison of the virological
data from these two studies, graphs of median virus titers have
been reproduced in Fig. 1 and 2. The results from both studies
show similar trends, with reductions in virus shedding in all the
IN plus IH groups compared to the placebo group. In the BID
and QID treatment arms of NAIB2008, there was a statistically
significant reduction in virus shedding from the placebo group
(P 5 0.005 and P 5 0.021, respectively, for AUC determina-
tions). In addition, the duration of virus shedding was reduced
below the limit of detection in the IN plus IH groups by 1 to 2
days compared to the placebo groups. From this comparison, it
is apparent that the greatest differences in virus titers were
observed at day 2 within 24 h of initiating therapy with zana-
mivir. This appears to be due mainly to the fact that placebo
virus titers have not dropped significantly at day 2 but by day 3,
there are considerable reductions in virus shedding in the pla-
cebo group. Although virus shedding continues to drop in the
treated groups, this is partly masked by the reductions in titers
in the placebo group. No reemergence of virus after cessation
FIG. 1. Clinical study NAIB2005. Median viral titer versus day of study is
shown. }, placebo (n 5 16); n , IH zanamivir (n 5 19); , IH plus IN zanamivir
(n 5 16). P 5 0.623, IH versus placebo; P 5 0.3, IH plus placebo, by AUC
analysis. Limit of detection, 1.5 log10 TCID50s/ml.
FIG. 2. Clinical study NAIB2008. Median viral titer versus day of study is
shown. }, placebo (n 5 14); , IH plus IN zanamivir BID (n 5 13); F, IH plus
IN zanamivir QID (n 5 13). P 5 0.005, BID versus placebo; P 5 0.021, QID
versus placebo, by AUC analysis. Limit of detection, 1.5 log10 TCID50s/ml.
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of treatment was observed. Overall the reductions in virus
titers in the two studies show a 1.6 to 2.1 log10 reduction in
mean virus shedding and a 1.5 to 3.75 median log10 reduction
in virus shedding at day 2. This contrasts with the results
obtained for the IH-only group, where no significant reduc-
tions in virus titers compared with placebo were observed.
These results indicated that with IH treatment alone, insuffi-
cient compound was reaching the nose to affect virus growth,
and this has been confirmed with g-scintigraphy studies (un-
published data). Despite this, clinical efficacy was comparable
with IN plus IH administration of the compound and with IH
administration alone, suggesting that viral replication in the
nose has little clinical significance compared to the rest of the
respiratory tract.
Susceptibility of influenza virus clinical isolates to zanami-
vir in NA enzyme inhibition assays. A total of 15 (43%) ther-
apy isolates from NAIB2005 and 12 (46%) therapy isolates
from NAIB2008 were successfully grown together with base-
line isolates for susceptibility monitoring. Isolates with the
longest exposure to zanamivir were chosen for analysis and
some matched placebo controls were included. These matched
pairs of clinical isolates were evaluated for their susceptibility
to zanamivir in the NA enzyme inhibition assay. Twenty
matched pairs of clinical isolates from NAIB2005 were evalu-
TABLE 1. Zanamivir susceptibility of paired influenza virus clinical isolates from NAIB2005
Treatment group Virus subtype Subject Sample day Plaque reductionIC50 (mg/ml)a
NA IC50 (ng/ml)a,b
IN 1 IH B 2849 1 0.0003 6 0.0002 0.9 6 0.14
4 0.0002 3.5 6 3.11
B 2853 1 1.38 6 0.04 1.1 6 0.57
2 0.69 6 0.66 1.35 6 0.64
B 2867 1 27.80 6 24.75c 2.7 6 1.56
2 4.89 6 2.48 2.5 6 1.41
B 2868 1 0.004 6 0.006 0.8 6 0.28
2 0.012 6 0.021 0.9 6 0.00
B 2885 1 35.25 6 56.13c 2.3 6 0.71
2 33.73 6 57.39c 2.65 6 0.92
IN B 2861 1 0.25 6 0.10 2.45 6 0.78
2 NT 2.05 6 0.49
4 0.14 6 0.22 NT
B 2871 1 0.003 6 0.001 2.25 6 1.48
2 5.75 6 6.63 2.1 6 0.85
B 2878 1 0.74 6 0.83 1.5 6 0.71
4 0.4 6 0.35 1.55 6 0.78
B 2881 1 0.61 6 0.59 1.6 6 0.71
5 0.46 6 0.36 1.0
B 2884 1 0.84 6 0.63 1.5 6 0.71
2 0.28 6 0.13 1.4 6 0.85
B 2895 1 13.88 6 19.54 1.75 6 0.21
2 15.87 6 22.25 2.3 6 0.57
B 2897 1 NT 1.35 6 0.64
2 11.78 6 16.29 1.7
3 8.21 6 11.15 1.5
H3N2 2873 1 0.002 6 0.002 1.1 6 0.14
2 0.011 6 0.010 0.95 6 0.21
B 2909 1 33.42 6 57.66c 0.9 6 0.28
2 0.39 6 0.43 1.1 6 0.42
B 2910 1 1.40 6 1.97 1.6 6 0.14
4 15.80 6 22.34 0.9 6 0.57
Placebo B 2857 1 0.99 6 0.1 2.4 6 0.57
4 1.5 6 0.22 2.55 6 1.06
B 2862 1 0.17 6 0.15 1.25 6 0.07
4 0.04 6 0.06 1.3 6 0.85
B 2877 1 50.09 6 70.59c 2.35 6 0.92
2 37.12 6 52.02 2.7 6 1.13
B 2882 1 0.22 6 0.15 NT
4 0.1 6 0.05 NT
B 2865 1 1.04 6 1.16 2.3 6 0.57
2 1.09 6 1.33 2.25 6 0.49
Negative control B/Beijing/1/87 0.025 4.3
Positive control B/Beijing/Zrd .100 2080
a Values represent the means of at least two assays. NT, not tested.
b Results obtained in replicate assays varied at most by two- to threefold.
c One replicate had an IC50 of .100 mM.
d Zanamivir-resistant influenza B/Beijing/1/87 (HA, Val105-Ala, Leu2253Gln; NA, Glu1163Gly).
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ated for NA enzyme susceptibility, after first carefully deter-
mining virus enzyme input (Table 1). All 20 paired clinical
isolates were equally sensitive to zanamivir, with IC50s falling
in the range of 0.8 to 2.7 ng/ml. These values fall within the
range previously observed for clinical isolates (31). The in vitro
control influenza B zanamivir-resistant variant B/Beijing/1/87
isolate P3-12 and the wild-type B/Beijing/1/87 isolate gave
IC50s of 2,080 to 2,326 ng/ml and 4.3 to 14.3 ng/ml, respectively.
Out of a total of 19 pairs of clinical isolates from NAIB2008,
four pairs from the BID and QID treatment arms contained
insufficient levels of NA enzyme activity even after concentra-
tion to enable an assessment of zanamivir susceptibility to be
made. For the remaining 15 matched pairs where NA enzyme
susceptibility to zanamivir was measured, 13 showed no repro-
ducible difference between samples taken before and during
treatment, with IC50s ranging from 0.4 to 3.1 ng/ml (Table 2).
Again, these data are consistent with previously published data
(31). Two pairs of isolates collected from subjects 7257 and
7259 did demonstrate a small apparent reduction in suscepti-
bility to zanamivir during treatment. For isolates from subject
7259, a shift in susceptibility of two- to fourfold (mean, 3.6-
fold) was observed. For isolates from subject 7257, initial ex-
periments showed a shift in sensitivity of 5.6- to 11.3-fold
(mean, 7.8-fold); however, this was not reproducible in freshly
grown material (Table 2), where only one assay gave a shift in
susceptibility. The absolute values obtained for each isolate
from subjects 7257 and 7259 still fall within the range of those
quoted previously as being highly sensitive to zanamivir. The
matched isolates from subject 7257 were also sensitive to zana-
mivir in yield reduction assays with no shift in susceptibility
during treatment (data not shown).
Susceptibility of influenza virus clinical isolates to zanami-
vir in plaque reduction assays. As previously observed (31),
data from plaque reduction assays were highly variable, limit-
TABLE 2. Zanamivir susceptibility of paired influenza virus clinical isolates from NAIB2008
Treatment group Virus subtype Subject Sample day Plaque reductionIC50 (mg/ml)a
NA IC50 (ng/ml)a
QID H3N2 7222 1 0.04 6 0.02 C
2 0.05 6 0.06 C
H3N2 7232 1 0.04 6 0.02 0.9 6 0.57
3 0.05 6 0.06 1.65 6 0.35
H3N2 7241 1 .100 C
4 .100 C
H3N2 7228 1 0.04 6 0.05 0.75 6 0.35
3 0.09 6 0.05 0.95 6 0.78
H3N2 7249 1 .100 0.9 6 0.14
4 .100 0.75 6 0.21
H3N2 7257 1 .100 0.4 6 0.14
2 .100 3.1 6 0.42
BID H3N2 7227 1 .100 C
2 .100 C
H3N2 7244 1 .100 0.8 6 0.14
2 .100 0.6 6 0.28
H3N2 7256 1 .100 1.1 6 0.28
3 .100 2.75 6 1.63
H3N2 7230 1 0.22 6 0.12 C
2 50.29 6 49.72b C
H3N2 7259 1 NT 0.8 6 0.14
3 NT 2.85 6 2.05
H1N1 7239 1 .100 10 6 00
2 .100 0.95 6 0.07
Placebo H3N2 7229 1 .100 0.945 6 0.36
3 .100 1.25 6 0.35
H3N2 7237 1 .100 1.35 6 0.07
3 .100 1.4 6 0.71
H3N2 7248 1 NT 1.05 6 0.49
4 NT 1.05 6 0.35
H1N1 7231 1 NT 0.5 6 0.42
3 NT 0.5 6 0.42
H1N1 7242 1 .100 0.85 6 0.35
4 .100 0.9 6 0.28
H3N2 7250 1 NT 1.3 6 0.57
5 NT 0.9 6 0.57
H3N2 7258 1 NT 1.2 6 0.57
3 NT 1.05 6 0.35
Negative control B/Beijing/1/87 0.012 14.3
Positive control B/Beijing/ Zr c .100 2,326
a Values represent the means of at least two assays. C, insufficient NA activity following concentration; 76% of isolates were influenza A (H3N2); the remainder were
influenza A (H1N1); NT, not tested.
b One replicate had an IC50 of .100 mM.
c Zanamivir-resistant influenza B/Beijing/1/87 (HA, Val105-Ala, Leu225-Gln; NA, Glu116-Gly).
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ing the assay’s value in susceptibility monitoring. Data was
pooled from individual experiments to generate a geometric
mean value for each isolate (Tables 1 and 2). The in vitro
controls, influenza B zanamivir-resistant variant B/Beijing/1/87
isolate P3-12 and the wild-type B/Beijing/1/87 isolate, gave
IC50s of .100 and 0.012 to 0.025 mg/ml, respectively.
The susceptibility to zanamivir of the 20 paired clinical iso-
lates from NAIB2005 ranged from means of 0.002 to 50 mg/ml
(Table 1). Considerable variability was observed between rep-
licate assays for some isolates. For four isolates, at least one
replicate experiment gave a value of .100 mg/ml, the highest
concentration tested. Analysis of the data from paired isolates
showed that there was a consistent shift in sensitivity between
only two pairs of isolates: isolates from day 1 and day 2 from
patient 2871, a patient that had received IH zanamivir, and
isolates from day 1 and day 4 from patient 2862, a patient that
had received a placebo. The day 2 isolate from patient 2871
was approximately 2,000 times less sensitive to zanamivir than
the day 1 isolate (before treatment). For the isolates from
patient 2862, the day 4 isolate showed a fourfold higher sen-
sitivity to zanamivir than the day 1 isolate. No corresponding
change in NA susceptibility was observed for any isolate from
these two subjects. All of the paired isolates from the
NAIB2005 study plaqued reasonably well in tissue culture.
The paired clinical isolates from NAIB2008 were tested for
in vitro susceptibility to zanamivir by plaque reduction (Table
2). The isolates tested plaqued poorly in MDCK cells, forming
large but very diffuse plaques. Of the 15 pairs of isolates tested,
12 were apparently insensitive to zanamivir inhibition at the
highest concentration tested, 100 mg/ml. This included repre-
sentatives from all three treatment groups, including the pla-
cebo group. Only four pairs of isolates were susceptible to
zanamivir by plaque reduction, with a mean range of suscep-
tibility from 0.04 to 50 mg/ml. Although differences in suscep-
tibility were observed between pre- and intratreatment samples
for these isolates, the differences observed were not reproduc-
ible between assays. In addition to the matched pairs of clinical
isolates, six day 1 virus isolates from subjects 7240, 7261, 7233,
7246, 7247, and 7245, who had rapidly resolved shedding virus
(,30 h), were also tested for in vitro susceptibility to zanamivir
by plaque reduction. These isolates appeared to be insensitive
to zanamivir by plaque reduction, with IC50s of .100 mg/ml,
suggesting that plaque reduction data were not predictive of in
vivo efficacy. In addition, no correlation between plaque re-
duction susceptibility, baseline virus titer, and time to resolu-
tion of virus shedding was observed in isolates from the QID
treatment arm (Table 3). In the NAIB2005 study, in addition
to obtaining daily nasal-wash samples from a subset of subjects,
throat swabs were taken on day 6 from the majority of subjects.
There was no evidence, from the culture of day 6 swabs taken
from 256 subjects treated with zanamivir, that influenza virus
shedding rebounded after treatment had ceased.
In vivo susceptibility of isolates from subjects 2871 D2, 7241
D1, and 7249 D1. Ferrets were infected with the above influ-
enza clinical isolates and treated with zanamivir at 0.01, 0.1,
and 1.0 mg/kg. The progress of influenza infection in the ani-
mal model was monitored by measurement of core body tem-
perature, nasal-wash viral titer, nasal turbidity, and comparison
of these parameters in zanamivir-treated animals with sham-
treated animals (Tables 4 to 6). The concentration of zanami-
vir that inhibits nasal virus titers by 90% (AUC10) was deter-
mined as a measure of susceptibility to zanamivir for
comparison with the in vitro data. The in vitro susceptibility in
the plaque reduction and NA assays (IC50s) and the AUC10s
determined in vivo together with influenza A and B controls
have been tabulated to allow comparisons to be made between
the three assay systems used in this study (Table 7).
The in vivo susceptibility of influenza virus isolate 2871 D2
to zanamivir is summarized in Table 4. In ferrets infected with
isolate 2871 D2, the pyrexic response was completely inhibited
in all animals treated with 1 or 0.1 mg of zanamivir per kg,
respectively. All animals treated with 0.01 mg of zanamivir per
kg had pyrexia between days 2 to 6 postinfection, but temper-
atures were statistically lower than those of control animals
(P # 0.01), which all had a marked pyrexic response 2 to 3 days
after infection, with elevated temperatures recorded up to day
6. Treatment with 1.0 and 0.1 mg of zanamivir per kg lowered
nasal-wash viral titers, compared with control values (P , 0.01
and P , 0.05, respectively). The dose required to reduce the
nasal-wash virus titer AUC to 10% of the sham-treated control
value was calculated as 0.82 mg/kg, similar to the value previ-
ously calculated for the laboratory influenza strain B/Victoria/
102/85 (Table 7). Nasal-wash turbidity was reduced to 35 and
20% of control values. The virus isolate 2871 D2 was sensitive
to inhibition by zanamivir in the NA assay, and this was con-
firmed by a full response to therapy in the ferret model. The
results obtained in the plaque reduction assay were, therefore,
TABLE 3. Lack of correlation of antiviral efficacy in MDCK cells
and response to zanamivir therapy in humansa
Subject and
day (D)
Plaque reduction
IC50 (mg/ml)
Pretreatment titer
(log10 TCID50/ml)
Day virus
undetectable
7222 D1 0.04 5.8 3
7228 D1 0.04 5.8 4
7232 D1 0.04 5.05 4
7240 D1 .100 6.05 2
7241 D1 .100 4.05 2
7249 D1 .100 4.3 5
7257 D1 .100 4.05 3
7261 D1 .100 4.8 2
a Subjects enrolled in the NAIB2008 clinical study were placed in a treatment
group receiving IH plus IN zanamivir QID.
TABLE 4. Efficacy of IN zanamivir in ferrets following infection with day 2 isolate from subject 2871 (virus 2871 D2)a
Treatment dose
(mg/kg)
No. of animals with
pyrexia/no. treated
Mean body temperature
AUC (% control)
Mean nasal-wash virus AUC
(TCID50)
Mean nasal-wash virus titer
(% of control)b
Mean nasal-wash turbidity
(% of control)
1.0 0/4 3.3* 4.93 10.57** 65.4
0.1 0/4 6.8* 5.17 18.62*** 80.4
0.01 4/4 52.0* 5.79 77.65 103.7
Vehicle 4/4 100 5.90 100 100
a *, significantly different from untreated control (P 5 0.01 by Duncan’s multiple range test); **, significantly different from untreated control (P # 0.01 by Dunnett’s
test); ***, significantly different from untreated control (P # 0.05 by Dunnett’s test).
b Virus titrated in triplicate for each time point for individual ferrets.
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not predictive of results obtained in either NA or in vivo assays.
(Table 7).
In ferrets infected with influenza virus isolate 7241 D1, the
pyrexic response was completely inhibited in animals treated
with 1 mg of zanamivir per kg (Table 5). Ferrets treated with
0.1 to 0.01 mg of zanamivir per kg had elevated temperatures
2 to 6 days postinfection, although these were statistically lower
than those of control animals at both doses (P # 0.01). Treat-
ment with 1.0, 0.1, and 0.01 mg of zanamivir per kg lowered
nasal-wash viral titers significantly compared with control an-
imals giving percent AUCs of 1.83, 3.99, and 15.63, respec-
tively. An AUC10 of 0.02 mg/kg for reduction in nasal-wash
viral titer was calculated and this compares well with the zana-
mivir sensitivity of the control virus, influenza A/Mississippi/1/
85, in this animal model system (Table 7). Nasal-wash turbid-
ities were reduced to 73.81, 79.76, and 92.26% of control values
at doses of 1, 0.1, and 0.01 mg/kg, respectively. The virus isolate
7241 D1 was shown to be highly sensitive to zanamivir in the
ferret model. Low levels of NA activity in influenza clinical
isolate 7241 are therefore not predictive of poor efficacy of
zanamivir in vivo.
The numbers of animals with a pyrexic response and the
magnitude of response following infection with influenza virus
isolate 7249 D1 are shown in Table 6. All sham-treated control
animals infected with influenza virus isolate 7249 D1 had a
pyrexic response within 2 to 4 days postinfection. In contrast,
the temperature responses of zanamivir-treated ferrets were
completely suppressed in all animals at doses of 1 or 0.1 mg/kg
and significantly reduced at 0.01 mg/kg (P # 0.01). Significant
reductions in nasal-wash virus titer were observed on days 1 to
6 postinfection at all doses tested, with reductions to 7.0, 6.8,
and 21.7% of control values (AUCs, days 1 to 6) at doses of 1,
0.1, and 0.01 mg/kg, respectively. From these values, the
AUC10 was calculated as 0.10 mg/kg, which is comparable to
that of other influenza strains (Table 7). Clinical isolates 7241
D1 and 7249 D1 were both apparently not susceptible to zana-
mivir in the plaque reduction assay. However, both of these
isolates were highly susceptible to zanamivir in vivo, indicating
that the plaque reduction assay is not predictive of in vivo
susceptibility to zanamivir.
Sequences of the NA and HA genes. Sequences of the NA
and HA genes from matched isolates gathered before and
during treatment were compared to identify possible treat-
ment-induced changes. A total of 28 matched isolates from the
treated groups, including 7 influenza B isolates and 6 placebo
matched pairs, were sequenced. The nucleotide and predicted
amino acid sequences obtained from the clinical isolates were
also compared with the sequence data for prototype strains
predicted to be circulating during the 1994 to 1995 and 1995 to
1996 seasons. For these seasons, the prototype H3N2 strain
used for reference was A/Wuhan/359/95 (H3N2). Table 8 gives
a summary of the predicted amino acid changes observed in
the HA and NA genes during treatment. The majority of the
matched isolates sequenced (79%) showed no coding changes,
including the two influenza B matched isolates from
NAIB2005, which showed apparent shifts in susceptibility to
zanamivir by plaque reduction. Only four H3N2 isolates from
NAIB2008 had sequence changes in the HA and/or NA gene.
Isolates from subjects 7228 and 7249 had a predicted HA
coding change at residue 275Gly3Asp. However, this muta-
tion is not in a conserved region and has been observed in
other virus variants. Samples from subject 7230 showed a pre-
dicted coding change in HA1 at residue 135Arg3Lys. Al-
though this mutation is close to the primary sialic acid binding
site, the change is conservative and a known natural variant
and was present in several isolates at baseline in this trial.
Isolates with the 135Lys residue showed a range of suscepti-
bility to zanamivir in vitro, and two isolates (7241 D1 and 7249
D1) were highly susceptible to zanamivir in vivo in the ferret
model. Isolates from subject 7228 showed a predicted coding
change in NA at residue 20Ile3Met. This forms part of the
transmembrane region of the NA gene and is not conserved. A
limited search showed no other published variant sequences
that had a methionine at this location; however, in our study
we identified one other clinical isolate that had a methionine at
this location at baseline. Isolates from subject 7241 showed a
predicted NA coding change at residue 29Ile3Pro that is also
located within the transmembrane region of the NA, which is
not highly conserved. No changes were observed in NA resi-
TABLE 5. Efficacy of IN zanamivir in ferrets following infection with day 1 isolate from subject 7241 (virus 7241 D1)a
Treatment dose
(mg/kg)
No. of animals with
pyrexia/no. treated
Mean body temperature
AUC (% control)
Mean nasal-wash virus
AUC (TCID50)
Mean nasal-wash virus titer
(% of control)b
Mean nasal-wash turbidity
(% of control)
1.0 0/4 12.01* 2.97 1.83** 73.81
0.1 4/4 33.49* 3.43 3.99** 79.76
0.01 4/4 65.09* 3.64 15.63** 92.26
Vehicle 4/4 100 4.91 100 100
a *, significantly different from untreated control (P 5 0.01 by Duncan’s multiple range test); **, highly significantly different from untreated control (P # 0.01 by
Dunnett’s test).
b Virus titrated in triplicate for each time point for individual ferrets.
TABLE 6. Efficacy of IN zanamivir in ferrets following infection with day 2 isolate from subject 7249 (virus 7249 D2)a
Treatment dose
(mg/kg)
No. of animals with
pyrexia/no. treated
Mean body temperature
AUC (% control)
Mean nasal-wash virus
AUC (TCID50)
Mean nasal-wash virus titer
(% of control)b
Mean nasal-wash turbidity
(% of control)
1.0 0/4 2.9* 5.50 7.0** 57.4
0.1 0/4 14.4* 5.48 6.8** 93.8
0.01 3/3 50.7 5.99 21.7** 82.8
Vehicle 3/3 100 6.65 100 100
a *, significantly different from untreated control (P 5 0.05 by Duncan’s multiple range test); **, significantly different from untreated control (P # 0.01 by Dunnett’s
test); ***, significantly different from untreated control (P # 0.05 by Dunnett’s test).
b Virus titrated in triplicate for each time point for individual ferrets.
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dues previously shown to be involved with in vitro susceptibility
to zanamivir.
DISCUSSION
Zanamivir was designed to bind to the highly conserved
residues within the active site of influenza A and B virus NA.
Previous in vitro studies have shown that passage of various
influenza A and B strains in the presence of zanamivir results
in the selection of virus variants that have reduced susceptibil-
ity in vitro to zanamivir. Biological studies and sequence anal-
ysis of the viruses isolated from such passage experiments have
shown that reduced susceptibility to zanamivir in vitro can
result from amino acid sequence changes in either the viral HA
or NA or in both proteins (1, 2, 4, 8, 9, 16, 17, 18, 21, 26, 27).
The key mutation in the NA gene associated with the resis-
tance phenotype which produces a 30- to 40-fold shift in sus-
ceptibility is 119Glu3Gly (influenza A) or 116Glu3Gly (in-
fluenza B), which also reduces enzyme stability (4, 26). Several
mutations in the HA have been identified, including those at
residues K68R and G75E in HA2 and G135D, N145S, N150S,
T155A, S165N, S186F, K222T, V223I, R229I/S in HA1, some
of which appear to contribute to in vitro resistance and in some
cases to drug dependence (1, 2, 9, 17, 18, 21, 27). Interestingly,
one HA variant which caused high-level resistance in vitro
showed no change in susceptibility to zanamivir in vivo, indi-
cating that the HA mutation may not contribute to resistance
in vivo (21). Furthermore, a double HA-plus-NA mutant pos-
sessed significantly less resistance in vivo (10-fold) than in vitro
(100-fold) (1). These studies suggest that HA mutations iden-
tified in vitro may not be important in conferring reduced
susceptibility to zanamivir in vivo and that it may be NA mu-
tations alone that are critical. At present, however, the rela-
tionship between HA and NA mutations and zanamivir sus-
ceptibility in vivo is not clear. It is therefore important to
monitor virus susceptibility to different uses of the compound
in the clinic. In one clinical study of an immunocompromised
patient given 14 days of treatment with zanamivir, an influenza
B mutant with changes in both the HA (198Thr3Ile) and NA
(152Arg3Lys) regions was isolated, suggesting that HA mu-
tations may play a role in vivo. The mutation in NA reduced
the affinity of the enzyme for zanamivir and also reduced its
catalytic activity. This double mutant also had reduced infec-
tivity when evaluated in the ferret model. This clinical study
and the previous in vitro studies have confirmed that mutations
selected by zanamivir in the NA compromise enzyme stability
or function, leading to less-fit viruses. Interestingly, the mutant
virus was found to be sensitive to zanamivir in cell culture
systems, probably due to changes in receptor binding specific-
ity. This study highlighted problems associated with cell culture
systems, such as the MDCK plaque reduction assay, for mon-
itoring in vivo resistance (7).
In the clinical studies described here, susceptibility monitor-
ing was undertaken with both enzyme NA assays and plaque
reduction assays in MDCK cells. Here again as reported pre-
viously (31), the plaque reduction assay was found to be highly
variable and unreliable in monitoring resistance in clinical iso-
lates, whereas the NA assay was highly reproducible (Tables 1
and 2). This variability is probably explainable in part by the
observation that influenza viruses have a widely varying depen-
dence on NA activity for replication in cell culture and virus
may spread from cell to cell directly, bypassing the NA func-
tion. In contrast to the isolate obtained from an immunocom-
promised patient where the in vivo resistant isolate in cell
culture was highly sensitive, here some isolates were highly
sensitive in the NA assay but appeared resistant in the MDCK
cell plaque assay. Despite the variations in plaque reduction
observed in NAIB2005, only one matched pair of isolates
showed a consistent reduction in susceptibility to zanamivir.
However, many isolates from NAIB2008 appeared insensitive
by plaque reduction, even at baseline. The isolates from
NAIB2008 all formed large diffuse plaques, which made some
TABLE 7. Comparison of in vitro and in vivo susceptibility data for
influenza virus clinical isolates
Virus NA assay IC50(ng/ml)a
Plaque assay
IC50 (mg/ml)
Ferret nasal-wash
virus titers
(EDAUC10 mg/kg)b
2871 D2 (influenza B) 2.1 6 0.85 5.7 6 6.63 0.82
7241 D1 (influenza
A/H3N2)
Cc .100 0.02
7249 D1 (influenza
A/H3N2)
0.9 6 0.14 .100 0.1
A/Mississippi/1/85
(H3N2)
1.3 0.0047 0.32
B/Victoria/102/85 1.3 0.0017 0.59
a Although numbers are small, a rank correlation coefficient of 0.95 (P 5
0.0513) was observed on comparison of the NA assay and the in vivo assay.
b AUC10, the concentration of zanamivir that inhibits nasal virus titers by 90%
(calculated as 10% of the AUC), was determined as a measure of susceptibility
to zanamivir. ED, effective dose.
c NA activity was too low to assay.
TABLE 8. Summary of susceptibility data in vitro and coding changesa
Study/treatment
group Subject Sample day
Plaque reduction assay
IC50 (mg/ml)
NA assay IC50
(ng/ml)
HA coding
changesb
NA coding
changesb
NAIB2005/IH 2871 1 0.003 6 0.001 2.25 6 0.49
2 5.75 6 6.63 2.1 6 1.48 None None
NAIB2008/QID 7228 1 0.04 6 0.05 0.75 6 0.35
3 0.09 6 0.05 0.95 6 0.78 G275D* None
NAIB2008/QID 7241 1 .100 C
2 .100 C None L29P†
NAIB2008/QID 7249 1 .100 0.9 6 0.14
4 .100 0.75 6 0.21 G275D* None
NAIB2008/BID 7230 1 0.22 6 0.12 C
2 50.3 6 49.72 C R135K*‡ Y22F*
a All isolates with coding changes were influenza A (H3N2) isolates. Changes were observed in influenza virus clinical isolates during treatment with zanamivir in
studies NAIB2005 and NAIB2008.
b Results indicate a comparison between pre- and intratreatment samples. *, natural variation; †, transmembrane region; ‡, close to the primary sialic acid binding
site.
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plaque reduction assays difficult to interpret and may have
contributed to the susceptibility profile seen in tissue culture.
All the isolates studied failed to agglutinate chick erythrocytes
but agglutinated guinea pig erythrocytes efficiently (unpub-
lished data), indicating changes in receptor specificity relative
to the viruses that circulated in the previous influenza out-
break. In addition, a proportion of the isolates from NAIB2008
contained insufficient NA activity to enable susceptibility test-
ing in the NA enzyme assay. This variability in plaque reduc-
tion susceptibility profiles and levels of NA activity required
further investigation, and key isolates were evaluated in vivo
for a definitive answer regarding zanamivir susceptibility. Of
the three isolates examined, one (2871 D2) developed an ap-
parent reduction in susceptibility, as measured by plaque re-
duction, during treatment; one (7241 D1) was apparently in-
sensitive by plaque reduction at baseline; and one (7249) had
undetectable neuraminidase activity. All these isolates were
highly susceptible to zanamivir in the ferret model (assessed by
reduction of viral shedding over time), showing that the plaque
reduction assay was not predictive of zanamivir susceptibility in
vivo. Furthermore, there was no apparent correlation between
susceptibility of virus isolates by plaque reduction at baseline
and the time to clearance of virus (Table 3). This again indi-
cates the limitations of the plaque reduction assay as a predic-
tor of the susceptibility of virus to zanamavir in the clinic. Due
to the acute nature of influenza infection and the efficacy of
zanamivir, the number of paired pre- and intratreatment iso-
lates is relatively small, which precludes the use of statistical
analysis to determine the significance of this observation. In
addition, low-level NA activity did not influence susceptibility
to zanamivir in vivo. Data from this study indicate that the NA
enzyme assay is currently the only in vitro assay that is predic-
tive of in vivo susceptibility to zanamivir (rank correlation
coefficient, 0.95; P 5 0.0513). Furthermore, it should be
stressed that in all susceptibility assays, including assays of
enzyme activity, in vitro virus assays, and in vivo assays, the
IC50s determined will be influenced by the level of input virus
used. It is therefore essential to quantify virus and to standard-
ize the level of virus used for susceptibility assays to reduce
variability and to avoid incorrect reporting of resistance.
These results emphasize problems associated with the assays
currently used for monitoring susceptibility to NA inhibitors.
To address some of these problems, further assay development
is in progress. Firstly, a more sensitive chemiluminescent neur-
aminidase assay is being evaluated to allow monitoring of NA
susceptibility in viruses with low NA activity. Secondly, alter-
nate respiratory cell lines with a-2-6 sialic acid receptor spec-
ificity are being tested for sensitivity to influenza viruses, in an
attempt to find a cell system which is more representative of
the respiratory tract. Thirdly, other methods of evaluating the
antiviral activity of NA inhibitors in influenza virus-infected
MDCK cells have been investigated. Initial experiments in-
volved an ELISA-based assay that detects influenza A and B
nucleoprotein antigens to assess virus yield using a relatively
high input of virus. This assay was also found to be too variable,
depending on input, and not to be sensitive enough to accu-
rately evaluate zanamivir susceptibility with clinical isolates. In
addition, we evaluated the susceptibility of a small number of
isolates to zanamivir in MDCK cells in a 24-h yield reduction
assay where virus was quantified by plaque titration. The input
of virus used was found to be absolutely critical. Using an input
of 0.01 PFU/cell isolates that were sensitive in the NA enzyme
assay but not by plaque reduction were also sensitive by yield
reduction (data not shown). This yield reduction assay, how-
ever, is very labor intensive and is not applicable to the testing
of large numbers of clinical isolates. In addition, many influ-
enza virus clinical isolates do not plaque well without cell
passage, and assessment of virus input and resulting yield will
be necessary by other techniques.
Further characterization of matched clinical isolates by se-
quencing the HA genes, both HA1 and HA2, and the NA gene
was undertaken. The majority of isolates revealed no amino
acid changes between the matched pairs, although there were
changes from the baseline sequence of the prototype strain
A/Wuhan/359/95 (H3N2). This is attributable to the known
variability within the HA and NA genes of influenza clinical
isolates. Amino acid changes in either HA1 or in the trans-
membrane region of NA were observed in isolates for four
subjects (7228, 7230, 7241, and 7249) on zanamivir therapy.
However, all amino acid changes were conservative and re-
sulted in changes that are present in natural variants. None of
the amino acid changes identified from in vitro studies to be
involved with reduced susceptibility to zanamivir were ob-
served in these clinical studies.
In conclusion, there was consistency observed in results be-
tween susceptibility monitoring by the neuraminidase assay
and the in vivo ferret model plus the sequencing results. These
results indicated, in these two clinical substudies, that no zana-
mivir resistance had emerged during 5 days of therapy of acute
infection. In addition to the analysis of paired isolates, samples
in NAIB2005 were also taken from the majority of subjects on
day 6 for culture to check that virus had not reemerged 24 h
after treatment had stopped. No evidence of an increase in
virus shedding at day 6 was observed in a total of 256 treated
subjects. The NA assay has proved to be a reliable, rapid
system for monitoring the susceptibility of clinical isolates to
zanamivir and in conjunction with sequencing studies, is cur-
rently the best method for surveillance studies. Evaluation of
influenza virus isolates from zanamivir phase III treatment and
prophylaxis studies are in progress to continue monitoring the
susceptibility of clinical isolates to zanamivir.
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